The role of hydroxychloroquine during the periconception period for recurrent miscarriage – a prospective observational study
DOI:
https://doi.org/10.18203/2394-6040.ijcmph20253244Keywords:
Hydroxychloroquine, Recurrent miscarriage, Periconception care, Pregnancy outcome, Immunomodulation, Maternal healthAbstract
Background: Recurrent miscarriage (RM) remains a significant clinical challenge with multifactorial etiologies, many of which are immunological or unexplained. Hydroxychloroquine (HCQ), an antimalarial with immunomodulatory properties, has shown promise in improving pregnancy outcomes in autoimmune conditions. However, its role in RM, particularly during the periconception period, has not been extensively explored. Objective was to evaluate the safety and efficacy of hydroxychloroquine administered during the periconception period in women with a history of recurrent miscarriage.
Methods: A prospective observational study was conducted on 160 women with a history of ≥3 miscarriages. Participants were administered 200 mg of HCQ daily for three months prior to attempting conception. Comprehensive clinical, hematological, and biochemical assessments were performed at baseline and during follow-up. Adverse events and pregnancy outcomes were recorded.
Results: A total of 115 women (71.9%) conceived following periconception HCQ therapy. Among them, 45.2% had full-term normal vaginal deliveries, 26.1% underwent cesarean sections, and 15.7% experienced preterm deliveries, while 13.0% had first-trimester losses. Most participants (75%) were asymptomatic during therapy, with 12.5% reporting mild gastrointestinal symptoms and 6.25% experiencing transient hepatic enzyme elevations. Laboratory parameters remained stable, with no significant deterioration. HCQ was well-tolerated overall, and no new infections or seroconversions were observed.
Conclusions: Periconception use of HCQ appears to be a safe and potentially effective therapeutic option in improving conception and pregnancy outcomes in women with recurrent miscarriage. Further randomised controlled trials are recommended to validate these findings.
Metrics
References
Dimitriadis E, Menkhorst E, Saito S, Kutteh WH, Brosens JJ. Recurrent pregnancy loss. Nat Rev Dis Primers. 2020;6(1):98. DOI: https://doi.org/10.1038/s41572-020-00228-z
Rasmark Roepke E, Matthiesen L, Rylance R, Christiansen OB. Is the incidence of recurrent pregnancy loss increasing? A retrospective register-based study in Sweden. Acta Obstet Gynecol Scand. 2017;96(11):1365-72. DOI: https://doi.org/10.1111/aogs.13210
Naik PT, Murugan RB, Sagili H, Lakshminarayanan S, Muruganandhan P, Puliyullaveetti AT, et al. Impact of COVID-19 pandemic on maternity services and challenges faced by pregnant women delivering at a tertiary care centre in South India. Int J Reprod Contracept Obstet Gynecol. 2021;10(11):4090-6. DOI: https://doi.org/10.18203/2320-1770.ijrcog20214058
Naik PT, Radhakrishnan SD, Murugan RB, Sagili H, Lakshminarayanan S, Muruganandhan P, et al. Impact of COVID-19 pandemic on postpartum contraception services in women delivering at a tertiary care centre in South India. Int J Reprod Contracept Obstet Gynecol. 2021;10(12):4392-7. DOI: https://doi.org/10.18203/2320-1770.ijrcog20214444
Nirk EL, Reggiori F, Mauthe M. Hydroxychloroquine in rheumatic autoimmune disorders and beyond. EMBO Mol Med. 2020;12(8):e12476. DOI: https://doi.org/10.15252/emmm.202012476
Gajić M, Schröder-Heurich B, Mayer-Pickel K. Deciphering the immunological interactions: targeting preeclampsia with Hydroxychloroquine’s biological mechanisms. Front Pharmacol. 2024;15:1298928. DOI: https://doi.org/10.3389/fphar.2024.1298928
Clowse ME, Eudy AM, Balevic S, Sanders-Schmidler G, Kosinski A, Fischer-Betz R, et al. Hydroxychloroquine in the pregnancies of women with lupus: a meta-analysis of individual participant data. Lupus Sci Med. 2022;9(1):e000651. DOI: https://doi.org/10.1136/lupus-2021-000651
Nori W, Akram NN, Al-Ani RM. Update on hydroxychloroquine use in pregnancy. World J Exp Med. 2023;13(4):99-101. DOI: https://doi.org/10.5493/wjem.v13.i4.99
Singh M. Role of hydroxychloroquine in preconception period of recurrent miscarriage patients. Int J Reprod Contracept Obstet Gynecol. 2023;12:864-7. DOI: https://doi.org/10.18203/2320-1770.ijrcog20230690
Mirzaei M, Amirajam S, Moghimi ES, Behzadi S, Rohani A, Zerangian N, et al. The effects of hydroxychloroquine on pregnancy outcomes in infertile women: a systematic review and meta-analysis. J Med Life. 2023;16(2):189. DOI: https://doi.org/10.25122/jml-2022-0095
de Moreuil C, Hoxha A, Pasquier E. Hydroxychloroquine may be beneficial in preeclampsia and recurrent miscarriage. Br J Pharmacol. 2019;176(9):1272-84.
Dernoncourt A, Hedhli K, Abisror N, Cheloufi M, Cohen J, Kolanska K, et al. Hydroxychloroquine in recurrent pregnancy loss: data from a French prospective multicenter registry. Hum Reprod. 2024;39(9):1934-41.
Dernoncourt A, Hedhli K, Abisror N, Cheloufi M, Cohen J, Kolanska K, et al. Hydroxychloroquine in recurrent pregnancy loss: data from a French prospective multicenter registry. Hum Reprod. 2024;39(9):1934-41. DOI: https://doi.org/10.1093/humrep/deae146
Moini A, Sepidarkish M, Dehpour AR, Rabiei M, Abiri A, Pirjani R. The effect of hydroxychloroquine on pregnancy outcomes in patients with unexplained recurrent pregnancy loss: a placebo-controlled study “pilot study”. J Obstet Gynecol. 2022;42(8):3471-6. DOI: https://doi.org/10.1080/01443615.2022.2141615
Huybrechts KF, Bateman BT, Zhu Y, Straub L, Mogun H, Kim SC, et al. Hydroxychloroquine early in pregnancy and risk of birth defects. Am J Obstet Gynecol. 2021;224(3):290.e1-22. DOI: https://doi.org/10.1016/j.ajog.2020.09.007
Zhu Q, Wang J, Sun Q, Xie Z, Li R, Yang Z, et al. Effect of hydroxychloroquine on pregnancy outcome in patients with SLE: a systematic review and meta-analysis. Lupus Sci Med. 2024;11(2):e001239. DOI: https://doi.org/10.1136/lupus-2024-001239
Woon EV, Day A, Bracewell-Milnes T, Male V, Johnson M. Immunotherapy to improve pregnancy outcome in women with abnormal natural killer cell levels/activity and recurrent miscarriage or implantation failure: a systematic review and meta-analysis. J Reprod Immunol. 2020;142:103189. DOI: https://doi.org/10.1016/j.jri.2020.103189
Tang AW, Alfirevic Z, Quenby S. Natural killer cells and pregnancy outcomes in women with recurrent miscarriage and infertility: a systematic review. Hum Reprod. 2011;26(8):1971-80. DOI: https://doi.org/10.1093/humrep/der164
Downloads
Published
How to Cite
Issue
Section
